Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CRYSTODIGIN vs ADALAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium, which in turn promotes calcium influx via the Na+/Ca2+ exchanger, resulting in increased myocardial contractility (positive inotropy). It also has negative chronotropic and dromotropic effects via vagomimetic action.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Treatment of heart failure with reduced ejection fraction (FDA-approved),Control of ventricular response in atrial fibrillation and atrial flutter (FDA-approved)
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
0.5 mg intravenously over 2-4 hours, then 0.25 mg every 6 hours as needed up to a total of 1.5 mg in 24 hours.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
Terminal elimination half-life approximately 1.6–1.9 days (38–45 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Primarily renal excretion; minimal hepatic metabolism. Not significantly metabolized by cytochrome P450 enzymes.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Primarily renal excretion of unchanged drug; ~80-90% eliminated in urine, ~10-20% in feces via biliary excretion.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
~20–25% bound to plasma proteins, primarily albumin.
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
Vd approximately 5–10 L/kg, indicating extensive tissue distribution; clinical significance: large Vd means low plasma concentration relative to total body load, necessitating loading doses.
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Oral: 60–80% (variable, depends on formulation and gastrointestinal factors); Intravenous: 100%.
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
Cr Cl 10-50 m L/min: reduce dose by 25-50%; Cr Cl <10 m L/min: reduce dose by 50-75% or use alternative.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Loading dose: 10-20 mcg/kg intravenously over 2-4 hours; maintenance: 5-10 mcg/kg every 6 hours as needed.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
Start at lower end of dosing range (0.25 mg intravenously), adjust based on renal function and response, monitor for toxicity.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
None.
None
Narrow therapeutic index; toxicity can be life-threatening.,Hypokalemia, hypomagnesemia, and hypercalcemia increase risk of digoxin toxicity.,Electrolyte monitoring and dose adjustment in renal impairment.,Patients with acute myocardial infarction, myocarditis, or severe pulmonary disease may be at increased risk of arrhythmias.
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Ventricular fibrillation,Known hypersensitivity to digoxin or other digitalis glycosides,Hypercalcemia,Hypokalemia (uncorrected),Atrioventricular block (second- or third-degree) unless a pacemaker is present,Hypertrophic obstructive cardiomyopathy (relative contraindication)
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
Avoid high-fiber foods and large amounts of bran or pectin, as they may reduce absorption. Grapefruit juice may increase blood levels; limit consumption. Consistent dietary potassium intake is important; extremes (high or low) can affect drug action.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
Pregnancy Category C. First trimester: Association with fetal cardiac glycoside toxicity and malformations in animal studies; limited human data. Second trimester: Potential for fetal bradycardia and hypoxia due to placental transfer. Third trimester: Risk of neonatal digitalis toxicity, including arrhythmias and heart block.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
Excreted in breast milk in low concentrations (M/P ratio approximately 0.75-1.0). Considered compatible with breastfeeding; monitor infant for signs of toxicity (bradycardia, vomiting).
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
Increased volume of distribution and renal clearance in second and third trimesters may necessitate dose increases. Monitor serum digoxin levels and adjust to maintain therapeutic range (0.5-1.0 ng/m L).
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
Crystodigin (digitoxin) has a very long half-life (~5-7 days) requiring careful monitoring to avoid accumulation. Unlike digoxin, it is primarily hepatically metabolized, so renal impairment has less impact on dosing. Always check for drug interactions with CYP3A4 inducers/inhibitors. Therapeutic monitoring of serum levels is essential (target 15-25 ng/m L).
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Take exactly as prescribed; do not miss doses or double up.,Report any symptoms of toxicity: nausea, vomiting, visual disturbances (yellow-green halos), or irregular heartbeat.,Avoid over-the-counter medications without consulting your doctor, especially antacids and laxatives.,Keep regular appointments for blood tests to monitor drug levels and kidney function.,Do not stop suddenly; withdrawal can worsen heart condition.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CRYSTODIGIN vs ADALAT, answered by our medical review team.
CRYSTODIGIN is a Cardiac Glycoside that works by Cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium, which in turn promotes calcium influx via the Na+/Ca2+ exchanger, resulting in increased myocardial contractility (positive inotropy). It also has negative chronotropic and dromotropic effects via vagomimetic action.. ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CRYSTODIGIN and ADALAT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CRYSTODIGIN is: 0.5 mg intravenously over 2-4 hours, then 0.25 mg every 6 hours as needed up to a total of 1.5 mg in 24 hours.. The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CRYSTODIGIN and ADALAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CRYSTODIGIN is classified as Category C. Pregnancy Category C. First trimester: Association with fetal cardiac glycoside toxicity and malformations in animal studies; limited human data. Second trimester: Potential for fe. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.